Search

Celebrating 10 Years of the Wesfarmers Centre

A decade long partnership with Wesfarmers Ltd. and the Wesfarmers Centre of Vaccines and Infectious Diseases has led to world-class paediatric research and important collaborations fuelling the Centre’s trajectory towards easing the burden of infectious diseases.

DiabHQ Community Reference Group

We’re looking for more community members to help with our exciting next phase of the DiabHQ mobile app

Reference exome data for Australian Aboriginal populations to support health-based research

Our data set provides a useful reference point for genomic studies on Aboriginal Australians

Feasibility of conducting an early pregnancy diet and lifestyle e-health intervention: The Pregnancy Lifestyle Activity Nutrition (PLAN) project

A lifestyle intervention starting in the first-trimester pregnancy utilising e-health mode of delivery is feasible

The NICE-GUT trial protocol: A randomised, placebo controlled trial of oral nitazoxanide for the empiric treatment of acute gastroenteritis among Australian Aboriginal children

Diarrhoeal disease is the second leading cause of death in children under 5 years globally, killing 525 000 annually. Australian Aboriginal and Torres Strait Islander (hereafter Aboriginal) children suffer a high burden of disease.

Pacific Early Age Readiness and Learning (PEARL) Programme in Tonga

The (PEARL) Programme, implemented by the World Bank, aims to support Pacific Island Countries in building capacity to design, implement, and monitor evidence-based policies and programs for primary schools.

The Platform Trial In COVID-19 priming and BOOsting : The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2

PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. Here, we present data for second boosters among individuals aged 18-<50 and 50-<70 years old primed with BNT162b2 until Day (D) 84.

Hearing loss in Australian First Nations children at 6-monthly assessments from age 12 to 36 months: Secondary outcomes from randomised controlled trials of novel pneumococcal conjugate vaccine schedules

In Australian remote communities, First Nations children with otitis media (OM)-related hearing loss are disproportionately at risk of developmental delay and poor school performance, compared to those with normal hearing. Our objective was to compare OM-related hearing loss in children randomised to one of 2 pneumococcal conjugate vaccine (PCV) formulations.

Trends in treatment-seeking for fever in children under five years old in 151 countries from 1990 to 2020

Access to medical treatment for fever is essential to prevent morbidity and mortality in individuals and to prevent transmission of communicable febrile illness in communities. Quantification of the rates at which treatment is accessed is critical for health system planning and a prerequisite for disease burden estimates. 

The Contribution of Geogenic Particulate Matter to Lung Disease in Indigenous Children

The aim of this study was to assess the relationship between dust levels and health in Indigenous children in Western Australia